TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05125016: Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination With REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients With Metastatic Castration-Resistant Prostate Cancer

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 228 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$8,717,940

Rescue Site Savings

+$5,772,690

Unlock Full NCT05125016 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05125016 Rescue Dossier →